Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Minke W. Lucas, Judith M. Versluis, Elisa A. Rozeman, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 6, pp. 408-422
Closed Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Christian U Blank, Minke W Lucas, Richard A. Scolyer, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 18, pp. 1696-1708
Closed Access | Times Cited: 146
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Suzanne L. Topalian, Patrick M. Forde, Leisha A. Emens, et al.
Cancer Cell (2023) Vol. 41, Iss. 9, pp. 1551-1566
Open Access | Times Cited: 135
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Mark Yarchoan, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 294-311
Closed Access | Times Cited: 110
Chemoimmunotherapeutic Nanogel for Pre- and Postsurgical Treatment of Malignant Melanoma by Reprogramming Tumor-Associated Macrophages
Lu Tang, Cong Fu, Hening Liu, et al.
Nano Letters (2024) Vol. 24, Iss. 5, pp. 1717-1728
Closed Access | Times Cited: 17
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: comparison of 3-year data from PRADO and OpACIN-neo
Irene L M Reijers, Alexander M Menzies, Marta Lopez-Yurda, et al.
European Journal of Cancer (2024) Vol. 214, pp. 115141-115141
Closed Access | Times Cited: 6
Staphylococcus Aureus Membrane Vesicles Kill Tumor Cells Through a Caspase-1-Dependent Pyroptosis Pathway
Mengyang Li, Yuting Wang, He Liu, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 4007-4019
Open Access | Times Cited: 5
Single-cell technology for cell-based drug delivery and pharmaceutical research
Huihui Hu, Yunlong Fan, Jiawen Wang, et al.
Journal of Controlled Release (2025) Vol. 381, pp. 113587-113587
Closed Access
Transcriptomic signatures in peripheral CD4+T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation
Eleni Palli, Matthieu D. Lavigne, Panagiotis Verginis, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
The real-world treatment characteristic and efficacy of immune checkpoint inhibitors in non-small cell lung cancer: Data from a retrospective cohort study
Chenyang Zhang, Jun Shao, Xiaolong Tang, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112152-112152
Open Access | Times Cited: 3
Mapping the single cell spatial immune landscapes of the melanoma microenvironment
Jamie Magrill, Dan Moldoveanu, J. Gu, et al.
Clinical & Experimental Metastasis (2024) Vol. 41, Iss. 4, pp. 301-312
Open Access | Times Cited: 2
Ion-interferential cell cycle arrest for melanoma treatment based on magnetocaloric bimetallic-ion sustained release hydrogel
Z. J. Li, Xiaoyang Liang, Zitong Qiu, et al.
Chinese Chemical Letters (2024) Vol. 35, Iss. 11, pp. 109592-109592
Closed Access | Times Cited: 2
A multi-task deep learning model based on comprehensive feature integration and self-attention mechanism for predicting response to anti-PD1/PD-L1
Wang Ren, Qiumei Liu, Wenhua You, et al.
International Immunopharmacology (2024) Vol. 142, pp. 113099-113099
Closed Access | Times Cited: 2
Revisiting the CXCL13/CXCR5 Axis in the Tumor Microenvironment in the Era of Single-cell Omics: Implications for Immunotherapy
Xuanyu Gu, Dongyu Li, Peng Wu, et al.
Cancer Letters (2024), pp. 217278-217278
Open Access | Times Cited: 2
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma
Lotte Hoeijmakers, Irene L. M. Reijers, Christian U. Blank
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2319-2338
Closed Access | Times Cited: 6
Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma
Abraham L. Bayer, Darwing Padilla-Rolon, Sasha Smolgovsky, et al.
American Journal Of Pathology (2024) Vol. 194, Iss. 6, pp. 1007-1019
Closed Access | Times Cited: 1
Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma
Piotr Błoński, Anna M. Czarnecka, Krzysztof Ostaszewski, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 669-669
Open Access | Times Cited: 1
Emerging Indications for Neoadjuvant Systemic Therapies in Cutaneous Malignancies
Domingos Sávio do Rego Lins, Beatriz Mendes Awni, Ana Zelia Leal Pereira, et al.
Medical Sciences (2024) Vol. 12, Iss. 3, pp. 35-35
Open Access | Times Cited: 1
Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC
Zhenyun Yang, Qianyu Wang, Hu Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Immune Checkpoint Blockade in Melanoma – Earlier is Better?
Vincas Urbonas, Audrius Dulskas, Edita Baltruškevičienė, et al.
Acta medica Lituanica (2024) Vol. 31, Iss. 1, pp. 195-200
Open Access
Biphasic co-detection of melanoma aneuploid tumor cells and tumor endothelial cells in guidance of specifying the field cancerized surgical excision margin and administering immunotherapy
Zhengzheng Fu, Lína Zhang, Rongyi Chen, et al.
Cancer Letters (2024) Vol. 598, pp. 217099-217099
Open Access
Challenges in Adjuvant Immunotherapy after Resection or Ablation for High-Risk Hepatocellular Carcinoma at High-Risk of Recurrence
Masatoshi Kudo
Liver Cancer (2024) Vol. 13, Iss. 6, pp. 573-578
Open Access
Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced hepatocellular carcinoma
Zhenyun Yang, Qianyu Wang, Hu Li, et al.
Research Square (Research Square) (2024)
Open Access
Operables Melanom: Neoadjuvante Immuntherapie – eine vielversprechende Option
Frank Friedrich Gellrich
Trillium Krebsmedizin (2024) Vol. 33, Iss. 3, pp. 192-197
Closed Access
Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma
Chuanlei Wang, Wei Feng, Xiaodong Sun, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
The emergence of neoadjuvant immune‐over BRAF therapy in melanoma
Elisa A. Rozeman, Jason J. Luke
Cancer (2024) Vol. 130, Iss. 20, pp. 3409-3411
Closed Access
Page 1 - Next Page

Scroll to top